アンジェス MG（4563）
Contents
1. JUIUUIUUUUDUDDUUUUUUUUUUUUUUDDUNUUUUUDUUNUDODUUUU UDUDUUUUUUDDUDUUguUUUDDDHGFUDDUDUUUUUUDDDDDUD 0 UDDIUUUDUDUUUUUUDDUUUUUUUUDDDDU 200200000001 2001000 0 000000000002003000000000000000000000000 0 0 00 22000000000000000 00 20070 600 4000000 JnIUUDUDDUUUUUUUUUUDUUDUU UDDDDDDNIDDDDDUDD Foentainell ij Du 0 UU UU UU UU UU UID JUIUUIUUUDDUDODUUUUUUUDUUUUUUUDUUDUUUUDUUDUDODUUUU HOU 4000000000 200000000000 8000 000000000000 UOUUUUO 0 1200000000000000000000000000000000000 II UI I IU L 4 13 30 8 1 0000000000000000 19 27 70 4 0 0 0 014 0 O 0 FontaineV 0100000000000 escar http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved Sh 4563 SR Research Report 2014 10 292. NF KB 000000000 00000 ED E H E E EL E E E E EE D 000 Percutaneous Transluminal Angioplasty OOD esearch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved gt 2 Sh 4563 SR Research Report 2014 10 29 UUUUUUUUUUUUUUU NF B 5 2 000000 0000000000000000000000000000 0 000000000000000000
3. UDDDUUUUUUDDDUUUUUUUUDDDDUUUUUDUDOUD 20140 12000 UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU 20181 12 0000 0000 0 0 00 LU 20180 12 0 D DO D DE C D DO 0 UO 0 00000 00 7T 000 CELO ELO ELO EE BED D UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUOUUU UUUUUUUUUUUUUUUU UU DOUG 0 00 0000000000000000000000000 0000000000 0 20130 0 00 00000 0000 3790000 20130 500 0000 198900 00000 00000 20140 JUIUUIUUUUDDUDODUUUUUUUDUUUUUUDDUUUUUDUUNDODUUUU 000000 400000000000000000000 6 088 00000000 00000000000000000000000000000000 40 20140 000 491000000000 Sh esearch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved 2 4563 SR Research Report 2014 10 29 oo 20130 400000 000010 0 0000000 0000000000 1 00000 20130 5 U 1 989
4. 20130 0 20180 00000000 Lu 20140 4 HOUUU 491000 OEE UUUUUUUUUUUUU UUUUUUUUUUUUUUUUUUUO uulgus 0 20140 9 0000000000000 6 088 00 00000000000 000000 UUUUUUUUUUUUUUUUUUU UUUUUUUUU 0 0000000000000000 8000 http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved 4563 SR Research Report 2014 10 29 JUIUDIDUUDDUU 20140 2 UDUDDUUIUUUUUDCINDDDDDUUUUUUDDDUUUUUUUUDDDUDLD IUDUUUUUuUuUUDUunu 140 120 0 150 120 0 160 120 0 170 120 180 120 0 0000000000000000 oo 0000000 000000 Dg Ol I D 0000000 0 0000000000000000 0 0000000000000000 000000000 5 2016 2016
5. 0 0000000000000000000000 02019 0000000000 400 8 0 0000000 2007 00010 UDDNDDUUODUUDDDDUDUUUUUUDDDDDUUUUUUU 20080000 20100 0 0 0 1200000000 20120 120000 1200000000000000 20120 0000000000 000000000 00000 20280 22000000000000 20100000000000000000000000000000 20120 1000000 00000020130 3000 3700001 20130 5000 1 9890000000 0L L 00020130 8 20141 20 0000100000000 000000020140 9 000000000000 9 000000000 000000 UDDDDDDD DDDDDDDU 6 0880 0000000 00 000000000000 000 20180 120 000000000000000600 esearch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved 2 Sh 4563 SR Research Report 2014 1
6. O O E OU PMDA Pharmaceuticals and Medical Devices Agency U UU U U U U 0 00000000000000000000000000000000000000 8 20131 0000000000000000 20100 0000000000000000 0 00000 000 0000 0000 20 20149 0000000000000000 000 20199 202000 00000 00 0 00 00 0 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0000000000000 500 00000 0 00000 2 0000 0 0 0 0 0 0 0 00 0 0 300 400 0000 OUUU 20140 12000000000000 7500 8500 D U D CL UE CE CE OE EL DE DE DE 0 CI 0 0 L 0000 2 6000 2 400 D DU UO U D UO UO DD E CEU D UO 0 0 00000 0000 0000000000000000000000020130 121 00000000 0 Hi SW Strengths Weaknesses U U U U D U 0 000000 esearch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved 2 2 Sh Sha
7. DL esearch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved 2 2 Sh 4563 SR Research Report 2014 10 29 20141 90 DO D D D D VE CE OT 7T UT UT l UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU UUUUUUUUUUUUUUUUUUUUUUU iB E E E 0 0 2015 1000 20160000000000000000000000 3000000000000000000000000 Sh esearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 2 4563 SR Research Report 2014 10 29 2 HOO HOOOOOL 130 1200 140 1200 140 1200 7500 850 000 84 3 14 2 3 8 21 3 34 3 51 4 40 5 0000 454 493 390 517 559 651 1 120 000 21 7 25 5 19 3 2 4 23 0 32 0 187 5 0000 328 305 313 417 476 560 1 013 2 6000 2 400 000 00000 0000 337 292 317 437 437 562
8. 000000 20100 900 20100 900000000 Fest Track n I U U L M 0000000000000000000000000000000000000000000000 000000000000000000000000000000000000000000000 esearch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved 2 Sh 4563 SR Research Report 2014 10 29 Fast Track 0 000000000000000000000000000000 0000000 0000 20120 000000000000000000 20140 10000000000000 L D 100000000000000000000 UDDDDNDUDUDDUUDDDD 5 00 150000000000000000000000000000000000 3140000000000000 201800000 0 00000000000000000000000000000000010000 00000 89 0000000000 0 0 0000000000000000000000000000000000 0 00 0 0000000000000000000000000000000000
9. 100 07 11 110 00000000000 40 0 2 5 0000000 0 018 Fontaine 0 O 00 000000000000000000000000 4000000010 00 0000 00000000 00000000 00000000000 0000 000000 UUUUUUUUUUUUUUU 0000 00000000000000002008 0 0000000000000 l PMPATOOOAOOOMOOOWHOOOOOO 00000000000000000020100 9000 00000 000 0 0000 UUUUUUUUUUUUUUUUUUUUUUU 5000 20030 66 20 LU JUIUUIUUUUDUDDUUDUUUUUUUUUUUUUUDUUUUDUDUDUUUU 000000 JUIUUIUUUUDUDUUUUUUUDUUDUUUUDUDUUDUUUUUUUDUDUUUU JUIUUIUUUDDDUUUUUUUDUDUUUUDUDUUDUUUUDUUDUUUUUUDUu JUIUUIUUUUDUDUUUUUUDUUOUUUUDUDDOUUUUUUUDNUDODUUUU UOUUUUUUU 2007000 2010000 00000000000000000000000 000000 0000000000 0 20060001 0000000000 20090 1100 SPA Special Protocol Assessment
10. http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4563 SR Research Report 2014 10 29 0000 000000000000020130 12000000000 L L LU NF KB0 00L L L E E E E A E E E E EE E E a a E EEEO E D UDUIUDDUUUUDUUDDDUDUUUUUUUDSRUUDDDDUDUUUUUUUUUDD HOU 50000000 00000 JnIUUUUUDUUDDUUDDDUUDDUDUUUU UDUDIDDUIUUUUDDDDDUD 20070 12000 6150000000000 2008 12000000000 20130 100000000000000000000000000 00 20130 120000 24700000000 CRO Contract Research Organization 2006 120 1 92000000000000100000000000020070 12000000 0000000020130 120000 2740000000000000000000 0 20140 12000 3000000000000 0000000000 0000000000 2014 0 1200000304000000000000000000 200 3900000000 50000000 D UBBOHLBLL Ll TD diu 12000 30000000 00000000000000000000020130 100000000000 00
11. 2012 100000 0 000 00000 0000 0000 0 0 0 0 0000 00 0 000 5 0 00000000000000000000000000000000010000 0 00 0000000000000000000000000000000000 40 12000 20140 00 00000000000000000000000000 000000 4 00000 000000000000 2018 00000000000000000000000 2018000000000 SRU L 00000000000000000000000000000 2019 UOUUUUO A i 4 Shared ese ch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved 4563 SR Research Report 2014 10 29 00 00000000000 20190 2020 0000 060 0 0 0 00000 00 000 0 5900000000000000 1 000 UDDDUUUUD 400000000 0 0 00000 000000000000000000000000000000 0000000 UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUOUUU UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUOUUU UU 0 000
12. 0000 2007 00000000 0000 000 2008 00000 0 00 00000 U 8 0 Sh escar ch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved Shared U J 45631 SR Research Report 2014 10 29 U LLL LI 0000 090 1200 1001200 1101200 OOOO 586 287 243 00000 142 181 181 00000 00000000 444 106 63 0000 3 197 2 297 2 344 0000 68 83 81 00000 2 350 1 440 1 444 503 420 348 1 062 S15 348 000000000 779 775 819 104 123 123 aa 218 217 230 U 183 135 145 uut 2 611 2 010 2 101 0000000000 0 00 00000000000000000000000000000000000000000 091 1210 100 1200 1191200 0000 289 102 42 0000 89 97 90 000000 53 83 91 0000000000 SRO 00 1 00000000000000000000000000000000000000000 000 120 1200 1301200 445 491 242 271 15 8 187 212 2 230 1 854 129 131 1 200 1 025 312 247 374 274 901 699 121 72 224 139 197 197 1 785 1 363 120 1200 130 1200 159 35 132 151 110 120 26 113 2 50 0 20130 120000000000 55 20 LH DU DU U L L 43 20 00000 0000 140000000 00000 0 000000 00000 UUUDUDDUDUUDDUUUUUUDUUUNUUUDUUUUUUDUDUU UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU
13. 00000000 000000000 000 60 00000000000 00000000000 00000000 0000000000000 00000000000 00000000000 00000000000 0000000 0000000 0000000060000 0000 00000000000 000000000 00000000000 00000000 00000000 0000000000000 0000000 5851 00000000000 000000000 OOOO 0000000000 00000000 000000000000000 00000000000000000 00000000000 0000000 0 0000000000000000 Dico OOO 0000000000000 00000000000000000 0000000000060 0000000 0000000000060 KLab OOO 000000000000000 00000000 0000000000000 000000000000000000 00000000000 00000000000000000 0000000000000 0000000000000 00000000 0 0000000000000000000000 00000000 0000000000000000000000000000000000000000 0000000000000000000000000000000000000000000000000 00000000000000000000000000000000000000000000000000000000000 UDUDUUDDDUSRInc 1 0 000000000000000000 SRInc UUUDDUUUDUUUDUUDDDUDUUDDUU Shared Research 0 0 000000000000000000000 SR incl 0000000000000000000000000000000000000000000000000000
14. 20120 12000 910000 20130 120000 699000000000 2012 0 12 0 0 0 00000 00000 00 0000 0000000020130 22000 00 0 00000 000 0 0 0 000 0 10000000 esearch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved 2 Sh 4563 SR Research Report 2014 10 29 2 SW Strengths Weaknesses Strengths u 2007 00600 00000000 20060 6 00001000000 000000000000000 0000 00000000000 0000000000000000000000 201408 00000000000000 U UU 2016 JnIUDUUUUUUUUUUUUUUUUDUUDuUUunno 0 0 J Weaknesses 0000000000000000000000000 20140 99 000000 0 00000000000000 6 0880 0000000 20140 9900000 0000 7 1360 000
15. I 0000000000000000000000000 ViroMed Co Ltd Hj EH 0000000000 E J VM202 PAD 00000000 I 20141 0001000000000000000000 esearch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved gt 2 4563 SR Research Report 2014 10 29 00000 000 0 060 000 00000 UDDIUIUUDUUUUDDUUUUDDUUUDDUUUUDDUUUDU 45680 0000 UDDIUIUUDDUUUDDUUUUDDU 45080 0000000000000 06000 000 20140 40 00000000000000000000000 JnIUUUUIUDDDDDUUDUUUUUUUUUUDUDUUUDUUDDUOUUD HF 0000000000000000000000000000000 UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU UUUUUUUUUUUUUUUUUUUUZO14N 4000000000000 00000 0000000000000000000000000000000 UUBDOUDBDUUDLUU UDUDDUUUUUUDUDDUDUUUUUUDDDDUUUUU 3 209 000000000 UD 19000000000000000000000000000000000 28 1 00000 210 50 90 0 0 0 00000 000 0 0 0 00000 UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUOUUU 0000 2013 10 00000020140 0 000000000000000000000000000 UUUUUUUUUUUUUUU OUUU UUUUUUUUUUUUUUUOUN
16. 000 2016 000000000000 UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU 0 20130 110000000000000000000 2014000000000 0000 000000000000000000000000000000000000000 00 0 0 20000000000000000000000000000000 AU 00000000 B 00600 000 0 0 0 0 000 0 0 0 0 00 0 0 0 6 0 000 0 0 0 0 000 0 00000 00000000000000 59000 Option 0 00 Poor Option 200000000 39DDDDDUUUUUUDDD No option patients 000000000000000000000000000000 00000 U Poor option 5 00000000000000000000000000 00000 00000 0 0 0 00006 0000000000000000000000000000 1 0000 000000 0000000000000000000 2014 40000 Human Stem Cells Institute 00000000 0 0 Neovasculgen 0 O 0000000 HGF 202 U NVIFGFHI U 000000 FGFOOOOOOOOOAOOOOOOOOOOOOOOOOOOOOOOOG 2 Neovasculigeni 1 000000000000000000000000020110 9 The Russian Ministry of Healthcare and Social Development 00000000 20120 99 000000 0 VEGF Vascular Endothelial Growth
17. Shared Research Report 2014 10 29 Y Ln 2 3 3 3 3 3 unti MG 4563 SR Research Report 2014 10 29 EE EE EM EE MASS EE 4 5 5 NR ME _ _ e 4 RH RF FFF se RH FYN 7 NEN HUN ET 7 UA AREER _ _ ____ ____ __ _ 10 680 11 15 15 UR AN EN em 17 7 7 26 SW Strengths Weaknesses 28 TEUER 29 i ____________ 31 31 MT 32 33 i 34 Shared esearch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved 2 4563 SR Research Report 2014 10 29 x L LI 00000 0 0 0 000 00000 00019990 000000 6 70 000000000000000000000000 0 0000000000 20011 1200000000000000 00 U 020140 4D 000 0 00000000000000000000000000000000000000 HUHBOBHUHBUHBEUOOLEELEOELDEELDEELELEELELLLL 00000000000000000020181 1210000000000000000 0000000 OO 20140 121000 20170 121000000000000000000 20180 1210000000000000000000000000000000000 0 00000000000000000000000000000000000000 000000
18. 1 122 2 6000 2 400 000 00000 000000 367 286 319 438 439 530 1 122 2 6000 2 400 uU pu 0000000000 000 100000000000000000000000000000000000000000 2014 12000 3000 20140 12000 3000000000 282000 00000 28 000 000 000 0000000000 222000 0 18 70 0 0 000000000 60000 0 69 50 UUUUUUUUUUUUUUUUUUUUUUUUUUUUUU UDDDD 2 330 000 00 0 0 0 116 50UMUUUUUUUUUUUUUUUDUUD 109000 21 210000000000000 6330 0000000 UDD 237000000000 9500000000000 4 709000 0 137 1000 513000 0 2 70020 00000000000000 31000000000000000000000000 JOO 1400000000 209000 0000000000 9460 00 0 0 0 000 2 121000 000000 946000 00000 0000 0 0 0 00 0 00000 61000000 JUIUUIUUUUDUDUDUODUUUUUUUUUUUUUUUUUUDUDUDUUUU OOOO 960000000 118000000000000000000000000 13 2 0910 00 00000000 972000 00000 Shared esearch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved 2 w 4563 SR Research Report 2014 10 29 2014 12000 2000 0000
19. 0000000000000000000000000 1 0240 00 000 14 600 00000 00020120 120000000 0 0000000000000000 1900000000000 000 00000000 6400000000 HGF D D D E LU C U U U D D 00 00000000000000000010000000000000000000 FDAUUUUUUUUUUUUUUUUUUUU 20130000 SPADUDDDDDUULD 20130 11 D D OO D DD D D DE DE CT T 7T 7T UI L UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU AGFOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO NF B 00000 NF kB 2011 000 00 2013 00000000000 00 00000000000010000000000000000000000000 0000000 020140 5 0000 1 00000 0000 0 00000000000000000010000000000000000000 UU NFKBUUUUDUIUUUUUUUUDDUUUUUUUUUUUDUUUUUDUUUUUD 0 0000000000000000000000000 2013000000000 0000 0000 000 00000 00 00000000000000000000000000000000010000 15000000000000000000000000 esearch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved gt 2 Sh 4563 SR Research Report 2014 10 29 2013 UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU Shared esearch http www sharedresearch jp Copyright 2013 Shared Re
20. 0 0 00000000000 00000000000000000000000000 0 00000000000000010000000000000000000000 Ul L L 0000000000000000 2014 UNUIUUUDUUUUDUUUUUUDNDUDUUDUUUDUUUDUUUUUUUDUDUU JUIUDUIUUUUDUDUDDODUUUUUUUUUDUDDUUUUUUDUUNUDODUUUU UDUDUSRUUUIUUDUUUUUUDUDDDUUUDDDUUUUUUUDDDUDDUD JnIUUDUUUUUUUDUUUNUUUDUUUDUD 00 000000000000000020100 900000000000000 000 00000000000000000000000000000000 02013 11000000000000000000000000000000000000000 JnIUUDIUUUUUUUDUUUNUUUNUUDUUUUUD 0000000 20140 100 000 0000 0000 0 0 00000 000 0 0 0 000 L esearch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved 2 Sh 4563 SR Research Report 2014 10 29 l1OOOOOOOOOOOOOOOOOOAOOOOOOOOOeOOOOOOO 100000000 2015 000000
21. 0 29 0 00 00000000 000000000000 HOU 000000000000000000000000000000000000 00000 H usu mimo m sm min Du 00000000 ooooog 0000000000 000 00000000000 00000000 000000 00000 0000000 1000007 pon Ti 10007 pma RR 000 NF kB 000000 FR 00 a 000000000 00000000 00000000000 0000000000 0000000000 0 000000 gm min m 00000000 CIN H _ UOUUUU UOUUUU nme pe o Fete 000000 Jonononnnnn 00000000000 SRU U UUUOU HGFUOOOOOOOOOOO HGF 19840 00000 HGF Hepatocyte Growth Factori 000000000 019955 00 00000 00000 L UDDDDHGFIIUIUUUDUDDDDDUUUUUUUDDDUDUUUUUUHGFUDD JUIUUIUUUUDUDUUDDUUUUDUUUUDUUDDUNUUUUUUDDDUUUL UDUDDUIUUUUUDDUDUUUUUUHGFUDDDDUUUUUUUUUDDDDDUD a Shared esearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4563 SR Research Report 2014 10 29 Win EE
22. 000 0 44 60 00000 174000 2000000000 12000 20140 1370000 20 50 0 0000000000 36000 0 81 00 1 219000 00000 67000 0 25 3sg000000000000000 000000000 0000000000000000 3440000000000 816000 0 55 40 0 0000 00000 00000 326000 0 11 60 0 0 00 0000000000000000000000 270000000000 L 1600000000 00000000000 1 035 000 0000000000 63200 0 0 0 0 000 UD 98000 0000 00 6290 00 00 0 0 0 0 0 0 0 0 0 0 000 0 0 0 0 61000000000 9OOOOOOOOOOOOOOOOOOOAOOOOO 120000000000000000 969000 00000000 6520002000 2014 120000000 20140 120000000000000 82000 00000 34 300 200000000 000000000 55000 0 6 40 00000000000 27000 u 60 3000 0 00 0 000 0 00 0 DO OO 00 0 0 00 0 0 00 0 00 000000000000000000000 23 000 00000 00 5590 00000 0000000000000000 14 60 0 27000 000000000000000000000000000000000
23. 0000 0000000000000000000000000 SRinc 00000000 8 1 0 0 00000000000000000000000000000000000000 UDUDUUUDDDUUUUUDDUUDUDDDUSRInc 00000 0 0 00000 00 00000 00 0 000 0 0 000 0000000000000000000000000000 00000000000000000000000000000000000000000000000000000000000 000000000 J SR Inc 00 0 00000000000000000000000000000 http www sharedresearch jp LE EE EL E EE EE EE EE ET EE U U U Email info sharedresearch p 3 31 12 0000 03 5834 8787
24. 0000 020150 120 000 20170 120000000 200 30 00000000000000000000000000000050 6000000 0000000000000000000000000 150 00000 100000 00000 020140 41 0 DOE 0000000000000 020140 40000 0000000000000 20140 4000000000000000000 OO 00000000050 000000000000000000 0000 00000 UDDBDUL SRI LULULULULU Sh esearch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved 2 4563 SR Research Report 2014 10 29 i 00000 2013 120000600 UDDUDD 491000 000 10 50 0 00000 NF B 0 UU D D D D D D D DU 0 OEE BEL O D 0 00 00 0 0 0 12 3 212000 0 13 30 D JU 000 271000 51 000
25. 0000 20150 0000000000000 00000000000000000000000000 20130 1000001 000000 2015 0000 00000 0000 0 0 0 00 00000 000 0 000 JUIUDUIUUUUDDUDODUUUUUUUDUUUUUUDDUUUUUUUDUUDUDUUUU UOUUUUUUUO 000000000000000 CNJUUUDDDDUUIUUUUDDDDUUUUUUDDDDUUUUUUDUUDDD2015 JUIUUIUUUUDUDODUUUUUUUUUUUUUUDUNUUUUUDUDUDUDODUUUL Sh escar ch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved gt 2 4563 SR Research Report 2014 10 29 2 HOO UU 1999000000000000000000000 KOFO D DU HGF D I I I UU 0000 0000000000 000000 00000 0 CELO DE D DNA UUUUUUUUUUUUUUUUUUUUUUUUUUU UUUUUUUUUUUUUU UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUOUUU UU
26. 00000 8 cervical intraepithelial neoplasia 000000000000 000 UDUDDUUUDUDUUUUBLIUDDUUDDDDUUDD20131 4000000000 0 UDUUUUUUUDD UDHPIIIUUDDUUIUUUDUUUUUUUUUDDUUUUUDU LU CINHUDDUUUUUUDDDDUD OOOO 19000000000000000000000000000000000000 0 0 0 0 0 00 00 0 0 00 0 0 00 0 00000 0 0 0 0 0 O0 17000000000000000000000000000000000000000 70000 0 0 0 0 0000 000 0 0 0 000 L UCINDUUUDUUUUUUDDDUUUDOUD CINDDDLDLULULUCCU
27. 147000000000000 360 000 0 57 900 0000000000000 0 0 15 50 0 170000 1500000000000000000000000 476000 0000000000 328000 000000000 437000 000000 337000 0 U UU DILI 5100000000600 JUIUUIUUUUDUDODUUUUUUUDUUUUUUUUDUUUUUDUUDNUDODUUUU esearch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved 2 2 Sh 4563 SR Research Report 2014 10 29 0 0 00000000000000000000000000 439000 0000000 00000 367000 iD D Tu Shared esearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 2 4563 SR Research Report 2014 10 29 4 20147 12 7 130 12 14 1200 00000 nooo nooo LH UL 491 750 850 nooo 1 854 DDOD 131 00000 1 025 0000000000 699 2 400 2 600 1 363 00000 1 383 2 600 2 400 00000 LU EB U LI 1 410 2 600 2 400 0000 0000000000 20140 12000000000000 7500 850UUUUUUUUUUUUUUUU
28. 2013 Shared Research Inc All Rights Reserved 1 MG 45631 U LLL LI 00000 MGOOOO 072 643 3590 uum 1999 12 17 HP https www anges mg com index php 1800000 HOUUUOUUUUO JUUIUIUDDIUUDUUDUDDUD IRO DD http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved SR Research Report 2014 10 29 567 0085 00000000000000 70 150 0000000000000 40 HOUUU 20020 90 251 120 18000 https www anges mg com ir index php 03 5730 2641 Sh escar ch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4563 SR Research Report 2014 10 29 Ut 00000000000000000000000000000000000000000000000000000000000 0000000 5 00000000000 000000000 UD 0000000000000 UDIUDDDDDUDDUDDDDU 0 0000000000000000000 0 00000000000000 000000000000000000000 00000000000 UUUUUUUU 000000 00000000 00000000 00000000000000000 00000000 000000000 00000000000000000000
29. DULULULULUUDLUU esearch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved 2 Sh 4563 SR Research Report 2014 10 29 2 0 0 10 15000000 701000 00000000000000000 00000000000 DUDDU UUUUUUUUUUUUUU 00000000000000000000 UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU 0 0 JnIUUUDUUDUUDUUDUUUUUUUUUUUUDUUUNUUDUUDUU 0 00000000000000000000000000000000010000 226000000 00 00000 00000 0 0 00 0 20060 HOUUUUUUUUUU 20130 UUUUUUUUUUUUUUUUUUUUUUUUUUUU
30. UUU 000 2 6000 2 4000 0000000000 0 0 20130 1200000000000000000 0 0 0000000000000000000000000000000000 00000000000000000000000000 105000000000000 JOOOOOOOOOOAOOOOOOOOOOOAOASOOOOOOOOAOOOOOO 3UDDUUUUUUUUUDD 0 1200000000000000000000 20130 00000000 a Shared esearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4563 SR Research Report 2014 10 29 i 0000 0000000000000000000000 0 20180 12000 0 000 00000 00 000 2014 120 000 20170 12000000000000000 20141 12 000 20160 12 0 703000000 0 0 0000000000000000000000 0000000000000 UDUDUUUDDDDUDUUUUUUUDDDUUUUUD 3094000000000 SR 6 12000 20160 000 120 20141
31. UUUUUUUUUUUUU UUUUUUUUUUUUUUUUU 00000 00 000000000000000000000000000000000000 2014 4000000000 BU l 00000 O EO 000000000000000000 4563 SR Research Report 2014 10 29 0000000000000000000000000000000000000000000000 D0000000000000000000 00 Orphan Dru 00000000000000000 000 UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU HD HEH HOUUU 0 YIDDDDUUUDUUUUUUUDD 30000 10000000000000 1900000000000000000 JOO 0
32. UUUUUUUUUUUUUUUUUUUUUUUUUUUUU 1 4 7350000 0000000000000000000000000000000000000 9 134 1 021000000000000000000000000000 00000 10000 000 00000 0 0 0 00 0000 00 0 0 00 0 1000000 0000000000000000000000000000000000000 1 021 esearch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved gt 2 Sh 4563 SR Research Report 2014 10 29 UUUUUUUUUUUUUU UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUOU UUUUUUUUUUUMUOUUUUUUUUUUUUUUUUOUUUUUUUUUUUU JUIUUDUDDUUUUUUUUUUUUUUUUDUDUUDUUUDUUUUUUDD JUIUUDUDDUUUUUDUUUUUUUUUUUUDUUDUUUUUDUUUUUUDD 00000 104 Ug 0 3 80 2 49 2 44 Hu 2 21 1 75 1 18 1 00 0 58 EBE 0 54 UU 0 53 0000000000 5 0 00 20130 1200000 Shared esearch http www sharedresearch jp Copyright
33. UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUOUUU UUUUUUUUUUUUUUUUUUUUUUUUUUUUU UUUUUUUUUUUUUOUUU 0000 n 0000 2030 00000000000000000 00000 3050 000000000000000000000000 0000 30 70 01 000000000000000000000000000000 0 0000000000000000000000000000 0 00000000000000000000000000000000000000 00000 1020 0 00000 00000 0 000 20130000 8 amp 5 060 200600 2008 000 000000000000000000067 0 001000000 46 10 00000 1900 x 00600 7700000009000 60006000 0000000001000000000000000000 A Sh ch http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved 4563 SR Research Report 2014 10 29 UUUUUUUUUUUUUUU 20010 12000000000000000000 20140 400000000000000000000000000000000000000000 IUUDDDUDUUUUUUDDDUU 2000 3090000000000 UUUUUUUUUUUUUUUUUUUUUUUUUUUU UUUUUUUUUUUUUUUUUUUUUUUUUUUU C UUUUUUUUUUUUUUUUUUUUU 4 201800000
34. ggg 20100 90 wag Fast Track 7 OOOO 2012 100 THE LE ELO BICI Shared http www sharedresearch jp Copyright 2013 Shared Research Inc All Rights Reserved 4563 SR Research Report 2014 10 29 10 20130 20140 70 20141 70 220 0000000000000000 0000000 UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU 80 1 000 90 220 lI UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU u 0000000000 32 403 900 0000000000 00 32 403 900 1 1 2880 20140 90 50 0 90 300 00000 90 2900 000000 20140 70 310 0000 20141 8 10 C C C 10000000L UU L 000000600 9 3320 UU 0000000000 198000 00000000 9 1340 00 O OUL 0000000000000000000000000 9 134000 000 201300 UUUUUUUUUUUU
35. rch Inc All Rights Reserved 4563 SR Research Report 2014 10 29 x 7 2014 10 290 000000 MGUDDDUDUUUUUUDDDUDUUUUUUUD 2014 100 2700000 20140 12000 300000000000 20140 12000 300000000000000000 0000 0 0000 20140 100 10000000000000000 0000000000 1000000 0000 2000000 260000000 00000 00 0 0 00 0 0 00 IOUS EBE LE 2014 22 1 0000000000 00000 2014000 300000000000000000000 65 240 000000 21 140 10000 6 088 20140 90 300000000000000UU 0 0 00 53 5440 00 14 847 DU U U U U U U 20141 91 22000000000000000000000000000000000 UUUUUUUMOUUUUUUUUUUUUUUUUUU JnIUIUDUUDUDDDUUDUU 000000000000 1500000000 L UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU UDUIUIUUDDUUUDDUUUUDDUUUUDUUUUDDUUUDDDDUD 2014 10 0000000000000000000000000000000000000000 00000000 20180
36. red IU 45631 JUD 00000 SR Research Report 2014 10 29 0971200 100 1200 110 1200 120 1200 1301200 140 1200 OO 0000 586 287 243 445 491 7500 850 000 38 4 51 0 15 2 82 6 10 5 0000 2 611 2 010 2 101 1 785 1 363 A2 600 A 2 400 000 2 784 1 911 1 791 1 716 1 383 2 600 A 2 400 000 uuu WERE ERE 2 921 1 967 1 815 1 708 1 410 A2 600 2 400 000 uut Bid S PEE 000000000000 23 598 23 646 24 467 26 226 31 268 EPS 124 0 83 3 74 6 67 7 46 9 A68 17 A 62 93 EPS 00000000 DPS 271 7 175 1 125 8 60 3 107 9 00000 00000 Ba HARD 5 047 3 053 1 576 355 2 295 000000 5 935 4 143 2 635 1 342 3 305 000000 61 72 62 45 23 000000000 954 633 1 050 770 506 000000 212 157 142 103 70 0000 7 162 5 004 3 889 2 260 3 904 49 98 60 67 42 0000000 515 488 417 331 218 000000 649 716 601 507 345 uuuiuill 17 15 15 uult 17 15 15 0000 649 716 618 522 361 00000 6 513 4 288 3 271 1 739 354 3 271 1 739 3 544 0000000000000 o nN 000000000000000 2 225 1 843 1 706 1 631 1 457 000000000000000 531 952 768 7 27 000000000000000 12 12 368 387 3 390 OOOO 00000000000 0000000000000 00000 90 9 85 7 84 1 76 9 90 8 0000000000 0 00 000000000000000000000000000000000000000000 esearch http www sharedresearch jp Copyright C 2013 Shared Resea
37. search Inc All Rights Reserved 4 4563 SR Research Report 2014 10 29 lt UID U LI UN EN TONLE HB BO 20000 80 5 KEF ED o HE ETE EE 20010 100 00000000 00000000000 20010 100 HGFOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOAO 1999 121 20010 10 20020 40 SL IH 2002 60 aan gaagaaagag LU EL DL D D 20020 EE 8 CES E i EL 8 TE SE E B LE 20020 00000000000000 20030 90 EL LT ODE EE Omg mag 6 00000000 30 20040 Allovectin 7 E E 00000 0000 0000 0000 000 BH EE T DE IBI 00000 Naglazymel 000000000000000 2008 40 00000 00000 Naglazymel 00000008060 MH 0000000000 FDAU 0 20060 50 2006 12 20090 110
Download Pdf Manuals
Related Search